exRNAdisease

General Information

Database ID:

exR0080655

RNA Name:

RPS25

RNA Type:

mRNA

Chromosome:

chr11

Starnd:

Coordinate:

Start Site(bp):

119015712

End Site(bp):

119018691

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABI2	chr2	203328239	203447728	+
AC004922.1	chr7	99325879	99394653	+
AC091167.2	chr15	90249556	90272208	+
AC092647.5	chr7	55887277	55955239	+
ACAD9	chr3	128879596	128916067	+
ACSS3	chr12	80936414	81261210	+
ACTA1	chr1	229431245	229434098	-
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ADCK2	chr7	140672945	140696261	+
ADCY3	chr2	24819169	24919839	-
ADD1	chr4	2843857	2930076	+
ADD3	chr10	109996368	110135565	+
ADPRH	chr3	119579268	119589945	+
AFG3L2	chr18	12328944	12377227	-
AGFG1	chr2	227472152	227561214	+
AGK	chr7	141551278	141655244	+
AGPAT3	chr21	43865223	43987592	+
AICDA	chr12	8602170	8612867	-
AKAP13	chr15	85380571	85749358	+
AKAP17A	chrX	1591604	1602520	+
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-1248	chr3	186786675	186786701	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC026362.1	chr12	122975320	122982907	+
AC026464.2	chr16	69463844	69466264	+
AC121761.2	chr12	75333798	75334486	-
AC126365.1	chr17	20788071	20789584	+
AC132217.1	chr11	2129121	2129964	-
AD000090.1	chr19	35557956	35581954	+
AL021707.1	chr22	38739003	38749041	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference